Novice Karate Group (ages 8 & up)

According to MRFR, the Americas Cancer Immunotherapy Market will grow from USD 100.54 billion in 2024 to USD 118.27 billion by 2032, at a strong 15.32% CAGR. Cancer vaccines are emerging as a promising immunotherapy category, aimed at either preventing cancer or stimulating the immune system to fight existing malignancies. In the U.S., therapeutic cancer vaccines like sipuleucel-T have opened new avenues for personalized medicine, while mRNA-based platforms are being trialed for melanoma and other cancers. Canada’s biotech ecosystem is actively developing peptide-based and dendritic cell vaccines, supported by government research grants. In Latin America, cancer vaccine adoption is still in early stages, but multinational partnerships are enabling pilot programs in urban hospitals. With ongoing research into neoantigen targeting and combination use with checkpoint inhibitors, cancer vaccines could address unmet needs in difficult-to-treat cancers, ultimately broadening the market’s growth potential across the Americas.